VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2020 | Lintuzumab-Ac225 and CLAG-M for R/R AML

Guru Subramanian Guru Murthy, MD, Medical College of Wisconsin, Milwaukee, WI, discusses a Phase I study (NCT03441048) investigating the combination of lintuzumab-Ac225 and the CLAG-M standard chemotherapy regimen in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML). The results indicate that the combination is safe and relatively well tolerated, with no unexpected adverse events observed. The overall response rate (ORR) was 73%, of which 67% of participants achieved a complete response (CR). 70% of participants showed measurable residual disease (MRD) negativity as measured by flow cytometry. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter